Skip to main content

ASCPT 2025 Annual Meeting Main banner

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

R
PII-037
REAL-WORLD CHARACTERIZATION OF DRUG-DRUG INTERACTIONS AMONG PATIENTS WITH ONCOGENE-DRIVEN NON-SMALL CELL LUNG CANCER USING TYROSINE KINASE INHIBITORS

Favorite
OAI-003
REAL-WORLD CLINICAL OUTCOMES BY P2Y12 INHIBITOR THERAPY AND GENOTYPE IN BLACK VERSUS NON-BLACK PATIENTS FOLLOWING PCI.

Favorite
PT-008
REAL-WORLD CLINICAL OUTCOMES BY P2Y12 INHIBITOR THERAPY AND GENOTYPE IN BLACK VERSUS NON-BLACK PATIENTS FOLLOWING PCI.

Favorite
E-002
REDUCTION IN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) OBSERVED WITH DORAVIRINE (DOR) IS CAUSED BY INHIBITION OF ORGANIC CATION TRANSPORTER 2 (OCT2)

Favorite
PII-114
RELATIVE IMPACT OF CYP2D6 GENOTYPE PHENOTYPE ON EXPOSURE OF SSRIS DURING PREGNANCY: EXTRAPOLATION APPROACH USING RWD AND PBPK MODELLING

Favorite
PI-014
RESULTS OF A PHASE 1 CLINICAL TRIAL (GH001-HV-103) TO DETERMINE THE SAFETY AND TOLERABILITY OF MEBUFOTENIN (5-MEO-DMT), ADMINISTERED VIA INHALATION (GH001) IN HEALTHY SUBJECTS.

Favorite
PI-038
REVERSE-TRANSLATIONAL FINDINGS FOR DATOPOTAMAB DERUXTECAN (DATO-DXD) HUMAN EFFICACIOUS DOSE PREDICTION BASED ON MECHANISTIC PK/TUMOR GROWTH INHIBITION ANALYSIS FOR PATIENT-DERIVED AND CANCER CELL LINE-DERIVED XENOGRAFT MICE.

Favorite